AI Article Synopsis
- * Researchers identified a specific G-protein-coupled receptor gene that is overexpressed in bladder cancer and other tumors, correlating high expression with poor patient prognosis.
- * The study highlights the potential of the drug GSK1070916 to inhibit the identified gene's effects, suggesting it could be a viable therapeutic option for bladder cancer treatment.
Article Abstract
Bladder cancer is one of the most severe genitourinary cancers, causing high morbidity worldwide. However, the underlying molecular mechanism is not clear, and it is urgent to find target genes for treatment. G-protein-coupled receptors are currently a target of high interest for drug design. Thus, we aimed to identify a target gene-related to G-protein-coupled receptors for therapy. We used The Cancer Genome Atlas (TCGA) and DepMap databases to obtain the expression and clinical data of . The results showed that was overexpressed in a wide range of tumor, especially bladder cancer. We also explored its effect on various types of cancer. High expression of was also shown to be significantly associated with poor prognosis. Cell models were constructed for cell cycle detection. sh can halt the cell cycle at a polyploid point. is a G-protein-coupled receptor signaling pathway-related gene with a significant effect on survival. We chose as a therapeutic target gene in bladder cancer. The drug GSK1070916 was found to inhibit the effect of via cell rescue experiments .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806424 | PMC |
| http://dx.doi.org/10.1080/21655979.2021.1971035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic value and immune landscapes of disulfidptosis‑related lncRNAs in bladder cancer.
Mol Clin Oncol
February 2025
Department of Urology Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Disulfidptosis, which was recently identified, has shown promise as a potential cancer treatment. Nonetheless, the precise role of long non-coding RNAs (lncRNAs) in this phenomenon is currently unclear. To elucidate their significance in bladder cancer (BLCA), a signature of disulfidptosis-related lncRNAs (DRlncRNAs) was developed and their potential prognostic significance was explored.
View Article and Find Full Text PDFEfficacy and safety of office-based diode laser ablation for recurrent low-grade non-muscle-invasive bladder cancer under local anaesthesia: A pilot study.
Arab J Urol
July 2024
Department of Urology, Urology Oncology Section, Hamad Medical Corporation, Doha, Qatar.
Introduction: Low-grade tumors account for approximately 50% of non-muscle invasive bladder cancer (NMIBC) with recurrence rates between 46% and 62%. Management of NMIBC recurrence typically involves transurethral resection of bladder tumor (TURBT) under general or regional anesthesia, which carries perioperative risks and considerable healthcare costs due to repeated procedures. Therefore, less invasive treatments such as office-based laser ablation, which aim to manage recurrences and reduce inpatient procedures without compromising oncological control, are needed.
View Article and Find Full Text PDFResection of sigmoid cancer with bladder invasion using laparoscopic combined with a cystoscopic holmium laser: comment.
Lasers Med Sci
January 2025
Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, 1120 NW 14th St #2107, 15th Floor, Miami, FL, USA.
Clinical significance of a new early diagnostic model for bladder cancer based on genome-wide microarray profiling of serum exosomal lncRNAs.
Int Urol Nephrol
January 2025
Department of Nuclear Medicine, Linyi People's Hospital, Shandong Second Medical University, 27 Jiefang Road, Linyi, 276003, Shandong, China.
Purpose: The aim of our report was to recognize bladder cancer (BC)-specific serum exosome-derived long non-coding RNAs (lncRNAs) profile for early diagnosis of BC.
Methods: Potential BC-specific exosomal lncRNA indicators were discerned by genome-wide microarray profiling analysis of serum exosomes from 10 healthy participants and 10 early stage BC patients (Ta and T1), followed by multi-stage validation through quantitative real-time PCR (qRT-PCR) in BC cells, culture solution as well as 200 serum specimens and 50 tissue specimens from non-muscle-invasive bladder cancer (NMIBC) patients. The diagnostic panel was established using logistic regression and evaluated by receiver-operating characteristic (ROC) curve.
Impact of late effects after treatment for bladder cancer with radical cystectomy on Quality of life: a case-control study.
Acta Oncol
January 2025
Aarhus University Hospital, Department of Urology, Aarhus, Denmark; Aarhus University, Department of Clinical Medicine, Aarhus, Denmark.
Background And Purpose: The gold standard when treating muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC), a procedure that holds the potential to affect the function of several pelvic organs, causing an impact on the patient's Quality of Life (QoL). Knowledge of the late effects following bladder cancer and treatment with RC is sparse. The aim is to describe the incidence of late effects and to investigate the impact on QoL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!